Coya Therapeutics, Inc.
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 26.8% | 2,474.1% | 133.3% | – | 99,254.1% | 2,021.9% | 4.2% | 0.2% | -131.3% | 1.1% | – | – | |
| – | 73.2% | -2,374.1% | -33.3% | – | -99,154.1% | -1,921.9% | 95.8% | 99.8% | 100.0% | 100.0% | 100.0% | 99.9% | |
| – | 30.0% | 2,493.9% | 133.3% | – | 99,254.1% | 2,021.9% | 2,238,841.6% | 81.8% | 169.5% | 1,635.1% | 2,063.9% | 234.0% | |
| – | 39.6% | 1,923.6% | 61.0% | – | 109,527.0% | 1,052.4% | 1,777,449.0% | 71.8% | 82.6% | 1,505.9% | 925.4% | 148.0% | |
| – | 42.9% | 1,948.7% | 61.2% | – | 109,877.4% | 1,055.0% | 4,016.3% | 153.6% | 252.3% | 3,142.1% | 2,991.1% | 382.2% | |
| – | 30.2% | -4,322.8% | -94.5% | – | -209,031.5% | -2,976.9% | -3,920.5% | -53.8% | -152.3% | -3,042.1% | -2,891.1% | -282.3% | |
| – | 2.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | 33.2% | -3,983.0% | -84.4% | – | -186,273.7% | -2,833.4% | -3,725.2% | -59.4% | -144.1% | -2,869.6% | -2,723.4% | -270.2% | |
| – | 12.1% | -28.7% | – | – | -36,899.9% | 279,320.7% | – | – | 0.1% | – | – | – | |
| – | 21.1% | -3,983.0% | -84.4% | – | -149,373.8% | -2,833.4% | -3,725.2% | -59.4% | -144.2% | -2,869.6% | -2,723.4% | -270.2% | |
| – | 33.6% | -4,297.7% | -84.2% | – | -185,923.4% | -2,830.7% | -3,721.0% | -59.2% | -143.9% | -3,037.0% | -2,722.3% | -275.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.